Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Razuprotafib - EyePoint Pharmaceuticals

Next Previous
X
Search
Drug Profile

Razuprotafib - EyePoint Pharmaceuticals

Alternative Names: AKB-9778; EYP-2301

Latest Information Update: 28 Jul 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble
  • Developer Aadi Bioscience; Akebia Therapeutics; Duke University; Harvard Medical School; Johns Hopkins University School of Medicine; Massachusetts General Hospital; Massachusetts Institute of Technology; Max Planck Institute for Molecular Biomedicine; Medical Technology Enterprise Consortium; New York University; Quantum Leap Healthcare Collaborative
  • Class Amides; Antineoplastics; Carbamates; Eye disorder therapies; Small molecules; Sulfonic acids; Thiazoles; Thiophenes
  • Mechanism of Action Angiopoietin modulators; Receptor-like protein tyrosine phosphatase inhibitors; TIE-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Diabetic retinopathy; Ocular hypertension; Open-angle glaucoma; Retinal vein occlusion; SARS-CoV-2 acute respiratory disease
  • No development reported Age-related macular degeneration; Breast cancer

Most Recent Events

  • 28 Jul 2022 No recent reports of development identified for phase-I development in Open-angle-glaucoma in USA (Ophthalmic, Drops)
  • 26 Aug 2021 Aadi Bioscience has merged with Aerpio Pharmaceuticals to form Aadi Bioscience
  • 11 Mar 2021 Aerpio Pharmaceuticals discontinues the phase II RESCUE trial in SARS-COV-2 acute respiratory disease in USA due to challenges associated with recruiting and monitoring patients (NCT04511650)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top